{"filings":[{"id":834679,"accession_number":"0001116463-26-000043","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-06-03T20:32:44+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"OraSure stockholders approve board declassification and 5M share increase in stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 5M share increase to Stock Award Plan; total authorized shares now 6,982,477.","Board declassification approved; transition to annual director elections over three years starting FY2027.","Three Class II directors (Bertrand, Boyd, McMahon) elected with >47M votes each.","Advisory 'say-on-pay' vote passed with ~45M for, ~6M against; Grant Thornton ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91386,"accession_number":"0001116463-26-000037","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q1 2026 results; specific financial figures not disclosed in filing excerpts","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Issued press release with Q1 2026 consolidated financial results.","Held webcast conference call with analysts and investors.","Provided investor presentation (Exhibit 99.2) with business developments.","Specific EPS, revenue, and guidance figures are not available in the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":27925000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91385,"accession_number":"0001193125-26-160336","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"OraSure appoints John D. Bertrand to board, enters cooperation with Altai Capital, seeks declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.","Altai Capital withdraws its director nominations and stockholder proposal under the Cooperation Agreement.","Board to propose amendment to declassify the board at 2026 annual meeting, phasing in annual elections.","Altai agrees to standstill and voting provisions; Bertrand joins Nominating and Corporate Governance Committee.","Bertrand co-founded Digital Diagnostics; brings AI/diagnostics experience to OraSure's transformation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101434,"accession_number":"0001193125-26-131979","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OraSure responds to Altai Capital, citing 40% TSR outperformance under CEO; $199M cash; product catalysts ahead","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).","Cash balance of $199M, no debt; $40M share repurchase program initiated in 2025 at avg price $2.85.","Gross margin improved 260bps over 3 years to 43%; SG&A reduced 37% to $73.8M; workforce cut ~40%.","Near-term catalysts: Colli-Pe urine collection device (~$0.5B TAM) and Sherlock CT/NG self-test (~$1.5B TAM).","Expects operating cash flow breakeven entering 2027; new products launching in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101433,"accession_number":"0001116463-26-000011","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David J. Shulkin resigns from OraSure board effective March 2, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Shulkin, M.D. resigned as director and from Compensation Committee, effective March 2, 2026.","Resignation is not due to any dispute with the Company, Board, or management.","Board expressed gratitude for Dr. Shulkin's service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101432,"accession_number":"0001116463-26-000009","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q4/FY2025 results; exhibit details not provided here","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release and investor presentation furnished on Feb 25, 2026 for Q4 and full year ended Dec 31, 2025.","No specific financial figures available in this filing excerpt; actual results are in Exhibits 99.1 and 99.2.","Company held a webcast with CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussing results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":115021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101431,"accession_number":"0001116463-26-000002","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.","Rapid CT/NG self-test is designed to deliver results in approximately 30 minutes in a disposable, over-the-counter format.","Colli-Pee device is intended for at-home urine collection, including for multiple STI indications.","No timeline for FDA clearance; approval would open new OTC market for OraSure in sexual health diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117802,"accession_number":"0001116463-25-000057","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OraSure CEO and CFO adopt 10b5-1 plans to purchase up to $165K each in common stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Carrie Eglinton Manner adopted a plan to buy up to $165,000 of OSUR shares over six months.","CFO Kenneth McGrath adopted a similar plan for up to $165,000 of OSUR shares over six months.","Trading under each plan begins after a cooling-off period of the later of 90 days from adoption or two business days after the 10-K filing, up to 120 days.","Both plans include required good faith certifications; officers have no discretion over transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117801,"accession_number":"0001116463-25-000053","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies Q3 2025 results announced; financial details not provided in filing exhibits","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company reported Q3 2025 consolidated financial results on November 5, 2025.","Specific revenue, EPS, and segment data are not available from the furnished exhibits.","Webcast held with CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath.","Investor presentation available on company website.","No guidance or material business developments disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88258000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117800,"accession_number":"0001116463-25-000049","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure board chair Aspinall resigns; Boyd appointed director, Kenny named chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mara G. Aspinall resigned from the board and as chair effective Oct 28, 2025; no dispute cited.","John P. Kenny, existing board member, appointed as chair effective same date.","Steven Boyd appointed as Class II director; term expires at 2026 annual meeting.","Boyd joins Audit and Nominating & Governance committees; initial equity grant of $100K in restricted stock vesting over 2 years.","Boyd determined to be independent under Nasdaq rules and Rule 10A-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134245,"accession_number":"0001628280-25-037806","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies reports Q2 2025 earnings; specific financial results not provided in extracted text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release for Q2 2025 consolidated financial results on August 5, 2025.","CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussed results and business developments on a webcast.","Detailed financial figures (revenue, EPS, segment data) are not included in the available filing snippet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":61173000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151025,"accession_number":"0001628280-25-025491","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve amendment to 2000 Stock Award Plan, increasing authorized shares by 6M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to Stock Award Plan to increase shares authorized for grant by 6,000,000 shares.","Three Class I directors elected: Carrie Eglinton Manner, John P. Kenny, David J. Shulkin, M.D., each with >54M votes for.","Ratification of Grant Thornton LLP as independent auditor for FY2025 passed with ~65M votes for.","Advisory vote on executive compensation approved with ~52M votes for.","At record date, 77,488,414 shares outstanding; broker non-votes on director elections were 7,988,307."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151024,"accession_number":"0001116463-25-000041","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure Chief Product Officer Kathleen Weber resigns, effective June 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen G. Weber notified resignation as Chief Product Officer on May 8, 2025.","Resignation effective June 30, 2025; treated as 'Good Reason' under Employment Agreement.","Weber eligible for severance benefits contingent on executing a general release of claims.","Employment Agreement and amendments previously filed in 2024 Annual Report on Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151022,"accession_number":"0001116463-25-000043","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2025-05-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.","Pro forma combined net loss $49.1M vs OraSure standalone net loss $19.5M for year ended Dec 31, 2024.","Pro forma diluted EPS ($0.66) vs standalone ($0.26) on 74.4M shares.","$17M in-process R&D intangible asset recognized for CT/NG test; goodwill $2.5M.","Contingent consideration fair value estimated at $22.9M ($15.9M milestone + royalties)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151023,"accession_number":"0001116463-25-000037","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q1 2025 financial results; specific figures not available in filing attachment","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated May 7, 2025 reports Q1 2025 consolidated financial results.","Management webcast held on same day; CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath discussed results and business developments.","No earnings per share, revenue, or guidance data included in the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":29931000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169919,"accession_number":"0001116463-25-000013","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OraSure announces $40M stock repurchase program, terminates 2008 plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $40M in common stock repurchases over two years on March 21, 2025.","Prior repurchase program from August 2008 has been terminated.","Repurchases may be through open market, privately-negotiated transactions, or Rule 10b5-1 plan.","Company retains discretion; no obligation to repurchase any specific amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169917,"accession_number":"0001116463-25-000008","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.","Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.","Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.","Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.","Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169918,"accession_number":"0001116463-25-000002","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.","Q4 2024 net income from continuing operations was $3.2 million ($0.26 per share), compared to $0.24 per share in the prior-year period.","Non-GAAP operating profit for Q4 2024 was $5.3 million, excluding $93,000 in amortization of intangibles and $0.4 million in stock option expenses.","Results were announced via press release and webcast on February 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":185827000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186966,"accession_number":"0001193125-24-285106","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"OraSure acquires Sherlock Biosciences for $5M upfront plus up to $20M milestones and royalties on CT/NG test","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.","Two milestone payments up to $20M aggregate tied to regulatory approval of Sherlock's CT/NG test.","Quarterly mid-single-digit royalties on CT/NG test net sales through 2034.","Sherlock becomes wholly owned subsidiary; convertible notes, preferred, and common stock receive allocated consideration.","Stock options terminated without payment; financial statements to be filed by amendment within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186965,"accession_number":"0001116463-24-000051","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.","The 8-K furnishes an investor presentation (Exhibit 99.1) with only a title slide; no new substantive details were given.","Acquisition press release referenced as Exhibit 99.2 but full text not included in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186964,"accession_number":"0001116463-24-000048","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure Technologies reports Q3 2024 results; details not in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release and conference call held November 6, 2024 for Q3 2024 results.","Management discussed financial results and business developments; no specific figures available here.","CEO Carrie Eglinton Manner and CFO Kenneth J. McGrath participated in the call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":148382000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203507,"accession_number":"0001116463-24-000042","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OraSure expands board to 7 members, appoints John P. Kenny as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 directors; John P. Kenny appointed as Class I director, effective Sept 6.","Kenny is independent under Nasdaq rules; will serve on Nominating and Corporate Governance Committee.","Initial equity award of $100,000 in restricted shares, vesting over two years, with pro-rata and change-of-control acceleration.","Term expires at 2025 Annual Stockholders Meeting; Kenny has no familial relationship with any director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203506,"accession_number":"0001116463-24-000034","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q2 2024 earnings; no figures in filing body","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued August 6, 2024, covering Q2 2024 results and business developments.","Conference call held same day with CEO and CFO discussing results.","Exhibit 99.1 (press release) not included in provided filing text; no specific numbers available."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":108467000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219951,"accession_number":"0001628280-24-024025","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2000 Stock Award Plan to increase authorized shares by 3,000,000; total now up to 5,302,283 shares.","Certificate of Incorporation amended to limit liability of certain officers as permitted by Delaware law; effective May 16, 2024.","Class III directors Nancy J. Gagliano and Lelio Marmora elected with ~57.2M and ~57.3M votes for, respectively.","Grant Thornton LLP ratified as independent auditor for FY2024 with 64.9M votes for; advisory say-on-pay approved with 57.5M for.","All proposals passed; no adjournment motion needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219950,"accession_number":"0001628280-24-021671","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure announces Q1 2024 results; specific figures not disclosed in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued May 8, 2024 covering Q1 2024 financial results.","Company held a conference call with analysts to discuss results.","No specific financial numbers are available from the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":54132000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219949,"accession_number":"0001193125-24-094797","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.05","7.01","9.01"],"status":"ready","headline":"OraSure reports cybersecurity incident with data exfiltration; Q1 revenue guidance reaffirmed","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Unauthorized third party gained access to certain information systems on or about March 27, 2024.","Company initiated response with cybersecurity experts, notified law enforcement; believes incident contained.","Certain files exfiltrated; investigating extent of sensitive or personal information involved.","Incident has not materially impacted operations, financial systems, or financial condition as of filing date.","Company reiterates previously communicated Q1 2024 revenue guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239697,"accession_number":"0001116463-24-000007","cik":1116463,"company_name":"ORASURE TECHNOLOGIES INC","ticker":"OSUR","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OraSure reports Q4/FY2023 results; press release not provided for review","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on Feb 27, 2024 announcing consolidated financial results for Q4 and FY2023.","Press release (Exhibit 99.1) referenced but not included in the submitted text.","No specific financial figures or business developments available for summary.","Item 7.01 also furnished for conference call remarks; no details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":405472000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":274017259.3045685,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}